{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:53:02Z","timestamp":1785912782193,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.hfc.2024.03.005","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T13:24:51Z","timestamp":1712237091000},"page":"343-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Specific Therapy in Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1016","volume":"20","author":[{"given":"Riccardo","family":"Saro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Allegro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldostefano","family":"Porcari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.hfc.2024.03.005_bib1","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.005_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.hfc.2024.03.005_bib3","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/bi301313b","article-title":"Age-related oxidative modifications of transthyretin modulate its amyloidogenicity","volume":"52","author":"Zhao","year":"2013","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.hfc.2024.03.005_bib4","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s10741-022-10237-7","article-title":"Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis","volume":"27","author":"Morfino","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"16","key":"10.1016\/j.hfc.2024.03.005_bib5","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.005_bib6","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1073\/pnas.1317488111","article-title":"Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis","volume":"111","author":"Mangione","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.hfc.2024.03.005_bib7","first-page":"1","article-title":"RNA targeting and gene editing strategies for transthyretin amyloidosis","author":"Ioannou","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.hfc.2024.03.005_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejim.2020.09.025","article-title":"Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery","volume":"82","author":"Porcari","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.005_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.hfc.2024.03.005_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A\u00a0review of patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol Ther"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.005_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hfc.2024.03.005_bib12","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/ajt.17009","article-title":"Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation","volume":"22","author":"Schmidt","year":"2022","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.005_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.hfc.2024.03.005_bib14","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hfc.2024.03.005_bib15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.005_bib16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.hfc.2024.03.005_bib17","unstructured":"Topline results from APOLLO-B phase 3 study of Patisiran. Available at: alnylampharmaceuticalsinc.gcs-web.com. https:\/\/alnylampha rmaceuticalsinc.gcs-web.com\/static-files\/dc61b882-9346-4394- 9f5c-dd322727742b. Accessed 11 September 2022."},{"key":"10.1016\/j.hfc.2024.03.005_bib18","unstructured":"Available at: https:\/\/www.businesswire.com\/news\/home\/20230520005007\/en\/Alnylam-Presents-18-Month-Results-from-the-APOLLO-B-Phase-3-Study-of-Patisiran-in-Patients-with-ATTR-Amyloidosis-with-Cardiomyopathy"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.005_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.17925\/HI.2023.17.1.27","article-title":"Patisiran for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy","volume":"17","author":"Ioannou","year":"2023","journal-title":"Heart Int"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.005_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ymthe.2016.10.019","article-title":"Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA Conjugate","volume":"25","author":"Zimmermann","year":"2017","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.hfc.2024.03.005_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"issue":"13","key":"10.1016\/j.hfc.2024.03.005_bib22","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: First Approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.hfc.2024.03.005_bib24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting n-acetylgalactosamine-small interfering ribonucleic acid coniugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hfc.2024.03.005_bib25","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"1\u20139","author":"Adams","year":"2022","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.005_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hfc.2024.03.005_bib27","first-page":"6416","article-title":"Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update","volume":"269","author":"Brannagan","year":"2022","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.005_bib28","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Hear Fail"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.005_bib29","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40120-021-00235-6","article-title":"Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-L(Rx) (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy","volume":"10","author":"Coelho","year":"2021","journal-title":"Neurol Ther"},{"key":"10.1016\/j.hfc.2024.03.005_bib30","unstructured":"Ionis presents positive results from Phase 3 NEURO-TTRansform study at international symposium on amyloidosis, Available at: https:\/\/ir.ionispharma.com\/news-releases\/news-release-details\/ionis-presents-positive-results-phase-3-neuro-ttransform-study. Accessed September 7, 2022."},{"key":"10.1016\/j.hfc.2024.03.005_bib31","unstructured":"CARDIO-TTRansform: A study to evaluate the efficacy and safety of eplontersen (formerly known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in participants with transthyretin-mediated amyloid cardiomyopathy (ATTR CM), Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04136171. Accessed January 5, 2024."},{"key":"10.1016\/j.hfc.2024.03.005_bib32","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.csbj.2019.05.006","article-title":"Applications of genome editing technology in animal disease modeling and gene therapy","volume":"17","author":"Li","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"issue":"6","key":"10.1016\/j.hfc.2024.03.005_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in\u00a0vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hfc.2024.03.005_bib34","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A\u00a0single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in\u00a0vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.hfc.2024.03.005_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hfc.2024.03.005_bib37","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.hfc.2024.03.005_bib38","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ehf2.13606","article-title":"Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery","volume":"9","author":"Porcari","year":"2022","journal-title":"ESC Hear Fail"},{"issue":"Supplement_2","key":"10.1016\/j.hfc.2024.03.005_bib39","doi-asserted-by":"crossref","first-page":"ehac544","DOI":"10.1093\/eurheartj\/ehac544.1767","article-title":"NNC6019\u20130001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial","volume":"43","author":"Fontana","year":"2022","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.hfc.2024.03.005_bib40","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMc2304584","article-title":"Antibody-associated reversal of ATTR amyloidosis\u2013related cardiomyopathy","volume":"388","author":"Fontana","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hfc.2024.03.005_bib41","article-title":"Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy","author":"Porcari","year":"2023","journal-title":"Eur J Intern Med"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713624000217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713624000217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:26:40Z","timestamp":1717590400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713624000217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1551713624000217"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2024.03.005","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specific Therapy in Transthyretin Amyloid Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2024.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}